Clinical Trial

Impact of Smoking on Ultrasound-Guided Infraclavicular Brachial Plexus Block Onset and Duration

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 1, 2025 (before its estimated March 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
The present study will be conducted involving 40 patients aged 18-65 years with ASA physical status I and II, scheduled for acute or elective hand or forearm surgery under the lateral infraclavicular block. Patients will be divided into two groups based on smoking status: Group I (non-smokers) and Group II (smokers who smoke ≥20 cigarettes/day for over 1 year). Using a high-frequency linear ultrasound transducer, the axillary artery, vein, and the three nerve cords will be identified in the lateral infraclavicular region. After disinfection with ethanol-chlorhexidine, a sterile drape will be placed, and the attending anesthesiologist will perform the ultrasound-guided infraclavicular brachial plexus block with a triple injection technique. A total of 10 mL of bupivacaine 0.25% and prilocaine 0.05% will be injected at all three nerve cords. The primary outcome will be the sensory blockade onset time, while secondary outcomes will include the duration of sensory and motor blockade, motor blockade onset time, time to first postoperative rescue analgesia, and total consumption of rescue analgesia. Postoperative pain will be assessed using the Visual Analogue Scale (VAS) within the first 24 hours at intervals of 2, 4, 8, 12, 16, and 24 hours. If VAS exceeds 30 cm, rescue analgesia with 0.05 mg/kg intravenous morphine sulfate will be administered.
Trial Details
NCT Number NCT06755229
Lead Sponsor Selcuk University
Conditions Smoking, Cigarette, Regional Anesthesia
Enrollment 40 participants
Start Date 2025-01-15
Primary Completion 2025-03-15 (estimated)
Study Completion 2025-03-20 (estimated)
Updated on ClinicalTrials.gov 2025-01-01